Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A look at the risks and rewards of hepatitis C treatment.
A meta-analysis has helped clear up conflicting previous evidence regarding this association.
University of Washington School of Medicine specialist comments on study findings published in JAMA Network Open.
Analysis of nearly 34,000 people finds no serious adverse events associated with direct-acting antiviral therapy.
Scientists have firmly established an association between direct-acting antiviral treatment and a lower risk of liver cancer and death.
The VA has cured HCV in nearly 100,000 veterans, which will dramatically reduce the development of advanced liver disease and liver cancer.
Do you know the benefits of successful hepatitis C treatment, along the risks associated with not trying treatment?
The U.S. FDA approved hepatitis C treatment Mavyret for children from ages 12 to 17 with all genotypes.
The U.S. Dept. of Veterans Affairs announced they are “on track to eliminate the hepatitis C in all Veterans willing and able to be treated.
Living with hepatitis C is risky.Untreated hep C increases risk of cirrhosis, liver cancer, and early death from all causes.
In fact, antiviral drugs account for nearly 14 percent of total drug costs in the program.
Direct-acting antivirals lower the risk of cardiovascular disease to a greater extent than interferon-based regimens.
Highlights some of the latest hepatitis C and liver disease research.
Find out if you are at risk for liver cancer even if your hepatitis C treatment was successful and you are virus-free.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.